Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

February 28, 2015

Conditions
Atrial FibrillationHeart Failure
Interventions
DEVICE

Reveal XT® Insertable Cardiac Monitor

If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).

OTHER

Heart Failure Risk Status Diagnostic

"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.~Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."

Trial Locations (11)

17602

Lancaster Heart & Stroke Foundation, Lancaster

28203

Carolinas Medical Center/Sanger Heart & Vascular, Charlotte

29425

Medical University of South Carolina, Charleston

37205

St. Thomas Research Institute, Nashville

43210

The Ohio State University, Columbus

49503

Spectrum Health, Grand Rapids

75390

University of Texas Southwestern Medical Center, Dallas

78503

Heart Clinic PLLC, McAllen

80012

Aurora Denver Cardiology Associates, Aurora

92037

Scripps Green, La Jolla

07450

The Valley Hospital, Ridgewood

All Listed Sponsors
lead

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

NCT01486316 - Diagnostic Device Risk Management of Atrial Fibrillation and Heart Failure | Biotech Hunter | Biotech Hunter